8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 11, 2010

TELEFLEX INCORPORATED
(Exact name of registrant as specified in its charter)

Delaware	1-5353	23-1147939
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

155 South Limerick Road, Limerick, Pennsylvania	19468
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: (610) 948-5100

Not applicable

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On January 11, 2010, Teleflex Incorporated (the “Company”) issued a press release and held a conference call to discuss its financial outlook for 2010. A copy of the press release is furnished as Exhibit 99.1 to this Current Report. A copy of the slide presentation referenced by the Company during the conference call, which was made available in advance of the call through the Company’s website, is furnished as Exhibit 99.2 to this Current Report. Portions of the press release and slide presentation include estimates regarding various aspects of the Company’s 2009 financial performance, and only such estimate information shall be deemed furnished pursuant to Item 2.02 of this Current Report.

The information furnished pursuant to Item 2.02 of this Current Report, including Exhibits 99.1 and 99.2 hereto, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

Item 7.01. Regulation FD Disclosure.

The information set forth in item 2.02 of this Current Report is incorporated by reference into this Item 7.01.

The information furnished pursuant to Item 7.01 of this Current Report, including Exhibits 99.1 and 99.2 hereto, shall not be considered “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

99.1 Press Release dated January 11, 2010

99.2 Investor Conference Call Slide Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 11, 2010	TELEFLEX INCORPORATED
	By:	/s/ Jeffrey P. Black
		Name: Jeffrey P. Black Title: Chairman, President and Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated January 11, 2010
99.2	Investor Conference Call Slide Presentation

EX-99.1

Exhibit 99.1

Jake Elguicze
Vice President
Investor Relations
610-948-2836

FOR IMMEDIATE RELEASE January 11, 2010

Teleflex Provides 2010 Business and Financial Outlook

Limerick, PA — Teleflex Incorporated (NYSE: TFX) will provide a preliminary financial performance outlook for 2010 and discuss its business plans and strategic initiatives in a conference call with investors today.

The company’s financial estimates for 2010 include total revenues in excess of $1.92 billion and diluted earnings per share from continuing operations excluding special items in the range of $4.10 to $4.25, or growth between 14% to 18% as compared to 2009. Cash flow from continuing operations is expected to be in the range of $275 to $280 million, or growth between 20% to 27% as compared to 2009.

Restructuring and other special charges related to the Arrow integration program are anticipated to be $0.05 per diluted share for the year.

“During 2010 we expect to achieve consolidated core revenue growth of between 2% to 3%, led by Medical segment core revenue growth of between 3% to 4%,” said Jeffrey P. Black, chairman and chief executive officer. “In addition, we expect to continue to expand our Medical operating margins, and anticipate they will approach 22% for the year.”

Black continued, “We also expect the cost reduction initiatives implemented in 2009 to drive margin expansion in both our Aerospace and Commercial segments. These operating margins, combined with our continued focus on reducing working capital, are expected to deliver another year of strong cash flow.”

Teleflex plans to report fourth quarter and year end 2009 financial results and to webcast a conference call with investors before the market opens on February 24, 2010. Further information will be available prior to the call.

As previously announced, Teleflex will hold a conference call today at 9:00 a.m. (EST). The conference call will be available live and archived on the company’s website at www.teleflex.com. In addition, an audio replay will be available from January 11 until January 15 by calling 888-286-8010 (US/Canada) or 617-801-6888 (International), passcode 69522110.

About Teleflex Incorporated
Teleflex is a diversified company with a significant presence in medical technology and niche businesses serving aerospace and commercial markets. Teleflex employs approximately 12,600 people worldwide who focus on providing innovative solutions for customers. Additional information about Teleflex can be obtained from the company’s website at www.teleflex.com.

Forward-looking information:
This press release contains forward-looking statements, including, but not limited to, statements relating to full year revenues and diluted earnings per share from continuing operations before giving effect to charges related to the restructuring and other special charges; expected cash flow from continuing operations; forecasts regarding restructuring and other special charges; expectations with respect to core revenue growth and Medical Segment core revenue growth; expected Medical Segment operating margins; and margin expansion in our Aerospace and Commercial segments expected to result from cost reduction initiatives implemented in 2009. Actual results could differ materially from those in these forward-looking statements due to, among other things, unanticipated expenditures in connection with the effectuation of restructuring programs; costs and length of time required to comply with legal requirements applicable to certain aspects of the restructuring program; unanticipated difficulties in connection with consolidation of manufacturing and administrative functions; customer reaction to the program; our ability to realize efficiencies; changes in material costs and surcharges; unanticipated difficulties, expenditures and delays in connection with the integration of Arrow International or our resolution of issues related to the FDA corporate warning letter issued to Arrow; our ability to meet our debt obligations; business conditions and the general economy, market opportunities, competitive factors, sales and marketing execution, shifts in technologies or market demand; and other factors described in Teleflex’s filings with the Securities and Exchange Commission.

###

EX-99.2

TELEFLEX INCORPORATED 2010 FINANCIAL OUTLOOK Exhibit 99.2

Forward-Looking Statements/Additional Notes This presentation and our discussion contain forward-looking information and statements including, but not limited to, such matters as forecasted 2010 net sales, core revenue growth, operating margins, pension expense, earnings per share excluding special items and cash flow from operations; expected 2010 segment net sales, core revenue growth and operating margins; expected costs and results with respect to our FDA remediation efforts; anticipated R&D investments within our Medical Segment; assumptions with respect to foreign currency, effective tax rate, capital expenditures, depreciation and amortization expense, repayment of debt and weighted average shares; expected integration costs and synergies associated with the Arrow acquisition; market trends, future business and financial performance; and other matters which inherently involve risks and uncertainties which could cause actual results to differ from those projected or implied in the forward-looking statements. These risks and uncertainties are addressed in the Company's SEC filings including its most recent Form 10-K. This presentation includes certain non-GAAP financial measures, which include forecasted 2010 earnings per share excluding special items and estimated historical adjusted cash flow from operations. These non-GAAP measures exclude the impact of restructuring and impairment costs, gain or loss on the sale of assets, tax payments related to gains on sale of businesses, and acquisition integration costs. Reconciliation of these non- GAAP measures to the most comparable GAAP measures is contained within this presentation. Segment operating profit is defined as a segment's revenues reduced by its materials, labor and other product costs along with the segment's selling, engineering and administrative expenses and noncontrolling interest. Unallocated corporate expenses, restructuring costs, gain or loss on the sale of assets, acquisition integration costs, interest income and expense and taxes on income are excluded from the measure. Core revenues and growth exclude the impact of translating the results of international subsidiaries at different currency exchange rates from year to year and the comparable activity of companies acquired or divested within the most recent twelve-month period. The following slides reflect continuing operations.

Conference Call Logistics The release, accompanying slides, and replay webcast available online at www.teleflex.com (click on "Investors") Telephone replay available by dialing 888-286-8010 or for international calls, 617- 801-6888, pass code number 69522110

JEFF BLACK Chairman and Chief Executive Officer

2010 Financial Outlook Net sales to exceed $1.92 billion Consolidated core revenue growth of 2% to 3% Minimal full year foreign currency tail-wind Overall operating margins of between 16% to 17% for the year Growth of 50 to 100 bps EPS excluding special items of $4.10 to $4.25 Growth of 14% to 18% Cash flow from continuing operations of $275 to $280 million Growth of 20% to 27%

2010 Medical Segment Outlook Net sales exceeding $1.5 billion Core revenue growth of 3% to 4% Core sales growth driven by: Continued penetration of infection prevention critical care product lines Growth in anesthesia product offerings New product introductions Increased investment in R&D, clinical education, and sales & marketing International markets Rebound in surgical instrument & OEM sales Continued expansion of GPO/IDN relationships Segment operating margins approaching 22% for the year

2010 Medical Segment Outlook North America EMEA AsLA OEM 646.8 494.6 165.7 149 North America EMEA AsLA OEM 667 515.7 173.4 156.9 Critical Care Surgical Cardiac Care OEM Other 938.9 283.7 70.2 149.3 14.2 Critical Care Surgical Cardiac Care OEM 973.7 298.1 69.9 156.8

2010 Medical Segment Outlook Product Family Core Growth Core Growth Critical Care 3% to 4% Volume 2% to 3% Surgical 3% to 4% Price Flat Cardiac Care Flat New Product Introductions 2% OEM 3% to 4% CFG Expirations (1%) Total Core Growth 3% to 4% Total Core Growth 3% to 4%

2010 Medical Segment Outlook - Research & Development Trend 2007 Actual 2008 Actual 2009 Outlook 2010 Outlook R&D - $ 23.506 42.454 51.955 61.804 R&D - % of Revenue 0.023 0.028 0.036 0.041 Note: excludes $21.5M, ~$4M and ~$2M of FDA remediation expense in '08, '09, '10 respectively

2010 Medical Segment Outlook - New Product Introductions Not dependent on any one single product or procedure Vitality Index ~10% in 2010; up ~ 200 bps over 2009 ~ 60% of new product introductions to occur from higher margin / more clinical vascular access & anesthesia products Continued focus on providing a comprehensive infection prevention solution Anti-microbial PICC launch targeted for mid-year PICC Wand Recently received 510k approval for Teleflex ISIS TM HVT TM endotracheal tube Cuff Pilot Laryngeal Masks ErgoPac CVC kits Crystal Clear Inner Cannulas Note: Vitality index is defined as sales of new products and line extensions introduced over the past three years.

2010 Medical Segment Outlook - Clinical Education Training Vascular Access Anesthesia Respiratory 146 95 1 Largest increases in vascular access focused around PICC care, vessel health and preservation programs Anesthesia training focused around awareness of regional anesthesia product offerings Respiratory training programs launching in 2010 focused around humidification fundamentals Vascular Access Anesthesia Respiratory 225 120 60

2010 Medical Segment Outlook - FDA Update and Outlook Assumptions At the end of 2009, the FDA began their inspections of the former-Arrow facilities covered under the corporate warning letter Company believes it has put in place the necessary remedial measures to address the concerns raised by the corporate warning letter; nonetheless, the FDA process is continuing Expect FDA inspections to be completed by the end of Q1 2010 2010 Outlook Assumptions: FDA remediation spending down from ~$22 million in 2008 and ~$4 million in 2009 to ~$2 million in 2010 Investment being made back into Research & Development, RA/QA infrastructure, and Sales & Marketing activities 2010 revenue negatively impacted by ~$10 million due to expiration of certain CFG's Outlook assumes FDA restrictions clearance in 2nd half of 2010

2010 Aerospace Segment Outlook Net sales of $185 - $195 million Core revenue growth of 3% to 4% Increase in wide-body cargo loading system shipments to Boeing & Airbus Reduction in narrow-body volume Repair revenues flat versus 2009 Increase in cargo container volume Low double-digit operating margins for the year Continued expansion of segment operating margins driven by increased volume and manufacturing efficiencies

2010 Commercial Segment Outlook Net sales of $230 - $240 million Core revenue decline of approximately 3% Increase in Marine volume offset by reduction in shipments of modern burner unit to U.S. Military Rigging services sales flat with 2009 Upper single digit operating margins consistent with 2009 levels Full year impact of cost reductions implemented during the course of 2009 and continued Marine sales shift to the aftermarket, offsets decline in higher-margin modern burner unit sales

KEVIN GORDON Executive Vice President and Chief Financial Officer

$3.90 to $4.00 $3.90 to $4.00 $4.10 to $4.40 Over $2,400 $280 to $290 6.9% 6.9% 5.7% 5.8% Note: 2008 & 2009 Cash Flow from Continuing Operations exclude tax payments of $90.2M & $97.5M, respectively related to gain on sale of businesses 2010 Outlook Financial Goals

Pension & OPEB expense declines ~ $2 million versus 2009 Foreign currency tailwind Euro assumed to be at approximately today's rates Annual effective tax rate: 30% Capex: $50 - $55 million Depreciation expense: ~$60 million Amortization expense: ~$45 million Reduced debt balance & low interest rates result in year-on-year decline of full-year interest expense Achieved Arrow aggregate annual pre-tax synergy goals of $70 to $75 million Weighted average shares of 40.25 million 2010 Outlook Assumptions

2010 Outlook Low High Earnings per share from continuing operations available to common shareholders on a GAAP basis $4.05 $4.20 Add-back special items $0.05 $0.05 Earnings per share from continuing operations before special items $4.10 $4.25 Amortization expense $1.12 $1.12 Earnings per share from continuing operations before special items and amortization expense ("Cash EPS") $5.22 $5.37 Cash flow from continuing operations $275 million $280 million

JEFF BLACK Chairman and Chief Executive Officer

Summary Medical core revenue growth of 3% to 4% Continued expansion of operating margins EPS excluding special items of $4.10 to $4.25, up 14% to 18% Cash flow from operations of $275 to $280 million, up 20% to 27% Completion of Arrow integration

QUESTION & ANSWER